肽给药量对肽受体放射性核素治疗第一周期肿瘤剂量学的影响及其与肿瘤生长抑素受体总表达的关系
回顾性分析小肠(n=141)和胰腺(n=62)神经内分泌肿瘤患者,均接受7.4 GBq 177Lu-DOTATATE治疗,制剂中肽量93至456 µg不等,基于第1、4、7天SPECT测量计算第一周期肿瘤和正常组织吸收剂量,并计算总肿瘤生长抑素受体表达(tTSSTRE)。结果显示,肽给药量与所测参数之间无相关性(均相对于tTSSTRE)。
要点
- 小肠(n=141)和胰腺(n=62)NET患者接受7.4 GBq 177Lu-DOTATATE,肽量93至456 µg。
- 基于第1、4、7天SPECT计算第一周期肿瘤和正常组织吸收剂量。
- 肽量与所测参数之间无相关性(均相对于tTSSTRE)。
核心结论
- 在该回顾性分析中,177Lu-DOTATATE制剂中肽给药量与肿瘤和正常组织吸收辐射剂量之间未显示相关性(均相对于总肿瘤SSTR表达)。
研究设计与样本
- 回顾性评估小肠(n=141)和胰腺(n=62)神经内分泌肿瘤接受PRRT的患者。
- 所有患者接受7.4 GBq 177Lu-DOTATATE,制剂中肽量93至456 µg。
- 基于输注后第1、4、7天SPECT测量计算第一PRRT周期肿瘤和正常组织吸收剂量。
- 总肿瘤生长抑素受体表达(tTSSTRE)于24小时后SPECT计算:以最高活性42%截止VOI勾画功能性肿瘤体积,乘以相应肿瘤VOI的SUVmean。
- 采用Spearman秩相关分析肽给药量与肿瘤和正常器官吸收剂量的关系(相对于tTSSTRE)。
主要发现
- 肽量与所测参数之间无相关性(均相对于tTSSTRE)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The accumulation of 177Lu-DOTATATE might be influenced by the amount of administered peptide in relation to the tumor somatostatin receptor expression. The effect of the administered peptide mass on the resulting absorbed dose in tumors and normal organs has not previously been assessed in relation to the patients' tumor load. METHOD: Patients with small intestinal (n = 141) and pancreatic (n = 62) neuroendocrine tumors (NETs) who underwent PRRT were selected for retrospective evaluation. All patients had received 7.4 GBq 177Lu-DOTATATE, and the amount of administered peptide in the preparation varied from 93 to 456 µg. The absorbed dose in tumors and normal tissue at the first PRRT cycle was calculated, based on SPECT-measurements at day 1, 4, and 7 post-infusion. The total tumor somatostatin receptor expression (tTSSTRE) was calculated on SPECT after 24 h by multiplying the functional tumor volume, delineated by 42% cut-off VOIs of the highest activity, with the SUVmean for the respective tumor VOIs. Spearman's rank correlation analyzed any relationship between the administered amount of peptide and the absorbed dose in tumors and normal organs, in relation to the patients' tTSSTRE. RESULTS: There was no correlation between the amount of peptide and any of the tested parameters in relation to tTSSTRE. CONCLUSION: In this retrospective analysis, no correlation between the amount of administered peptide in the 177Lu-DOTATATE preparation and the absorbed radiation doses in tumors and normal tissues was demonstrated in relation to the total tumor SSTR expression.
引用
- Jahn U, Garske-Román U, Sandström M, et al. Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression. EJNMMI Res. 2023. PMID: 37204528. doi:10.1186/s13550-023-00997-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。